BRIVERATAM 100

BRIVERATAM 100 contains Brivaracetam, a novel antiepileptic drug used as adjunctive therapy for the treatment of partial-onset seizures in patients with epilepsy. It binds selectively to synaptic vesicle protein 2A (SV2A), helping to stabilize nerve activity and reduce seizure frequency. Known for its favorable safety profile and rapid onset of action, BRIVERATAM 100 offers effective seizure control with minimal cognitive or behavioral side effects.

Key Features:

• Effective adjunct therapy for partial-onset seizures

• Fast brain penetration and rapid onset of action

• Favorable tolerability and safety profile

• Minimal interaction with other antiepileptic drugs